Chemotherapy CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers LEARN MORE
Beyond First Line Therapy A phase II study of pemigatinib plus durvalumab (MEDI4736) in previously treated advanced intrahepatic cholangiocarcinoma patients with FGFR-2 fusion or rearrangement LEARN MORE
Immunotherapy Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) LEARN MORE
Beyond First Line Therapy Phase IIb trial of pemigatinib in combination with atezolizumab and bevacizumab for treatment of advanced cholangiocarcinoma with FGFR2 fusion LEARN MORE
Chemotherapy Herizon BTC-302 An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard of care therapy alone for advanced HER2 positive biliary tract cancer LEARN MORE
Beyond First Line Therapy A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) LEARN MORE
Chemotherapy A single arm phase 2 study of Y-90 SIRT in combination with durvalumab (MEDI 4736) and gemcitabine/cisplatin in locally advanced, unresectable or metastatic intrahepatic cholangiocarcinoma LEARN MORE
Beyond First Line Therapy Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer LEARN MORE
Immunotherapy A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients with Locally Advanced, Recurrent, or Metastatic Biliary Tract Cancers LEARN MORE
Beyond First Line Therapy A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer LEARN MORE
